Effectiveness and safety of dupilumab in children with moderate-to-severe asthma in China: A retrospective real-world study

Effectiveness and safety of dupilumab in children with moderate-to-severe asthma in China: A retrospective real-world study

Saved in:

Bibliographic Details
Main Authors:	Lihong Sun, Yingtong Ye, Shunkai Huang, Xu Qin, Lijun Zeng, Yilin Guo, Lanying Cheng, Nanshan Zhong, Peifang Wei
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-04-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003508
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China
by: Yuyi Wang, et al.
Published: (2024-11-01)

Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma
by: Abraham Alí-Munive, et al.
Published: (2025-05-01)

Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma
by: Kenji Mizumura, et al.
Published: (2025-01-01)

Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study
by: Carlo Mümmler, MD, et al.
Published: (2025-11-01)

Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study
by: Mariele Morandin Lopes, et al.
Published: (2025-06-01)

The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases
by: Tingting Shi, et al.
Published: (2024-12-01)

Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis
by: Tengfei Tian, et al.
Published: (2025-04-01)

Achievement of Control of Severe Bronchial Asthma When Using Dupilumab
by: O. V. Kazmerchuk, et al.
Published: (2024-11-01)

Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma
by: Tomohito Takeshige, et al.
Published: (2024-12-01)

Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
by: Francesca Barei, et al.
Published: (2024-12-01)

Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis
by: Júlia Opolski Nunes da Silva, et al.
Published: (2025-08-01)

Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China
by: Yue Xu, et al.
Published: (2025-07-01)

Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness
by: Omar Z. Ameer, et al.
Published: (2025-08-01)

Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study
by: Yanhua Chen, et al.
Published: (2025-01-01)

Real-world safety and effectiveness of dupilumab for the treatment of atopic dermatitis: two-year post-marketing surveillance in Japan
by: Hidehisa Saeki, et al.
Published: (2025-07-01)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
by: Wen Wang, et al.
Published: (2023-07-01)

Clinical Effectiveness, Clinical Stability, and Effects on Serum Galectin-7 Levels of Dupilumab and JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World, Single-Center Analysis
by: Akihiro Horie, et al.
Published: (2025-05-01)

Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry
by: Neal Bhatia, et al.
Published: (2025-04-01)

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2024-12-01)

Correction: Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry
by: Neal Bhatia, et al.
Published: (2025-07-01)

Real-World Use of MART in Moderate–Severe Asthma: Results from the Italian WAMP Survey among Healthcare Professionals and Patients
by: Fulvio Braido, et al.
Published: (2025-08-01)

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
by: Jonathan I. Silverberg, et al.
Published: (2025-02-01)

Monoclonal antibodies in severe asthma: outcomes from real-world data
by: Silvia del-Barrio-Buesa, et al.
Published: (2025-08-01)

T cell immunophenotypes and IgE responses in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab
by: Davender Redhu, et al.
Published: (2025-05-01)

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01)

Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network
by: Henner Zirpel, et al.
Published: (2024-12-01)

Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) in Uncontrolled Moderate‐To‐Severe Asthma
by: Li Zhang, et al.
Published: (2025-08-01)

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?
by: Neenu Sebastian, et al.
Published: (2025-05-01)

The management of adults and children with moderate severity asthma
by: P.M. Jeena
Published: (2007-05-01)

Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission
by: Mona Al-Ahmad, et al.
Published: (2025-03-01)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01)

Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis
by: Maohua Chen, et al.
Published: (2025-08-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
by: Eugene R. Bleecker, et al.
Published: (2023-01-01)

Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions
by: Ian D. Pavord, MD, et al.
Published: (2025-08-01)

Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics
by: Michael E. Wechsler, et al.
Published: (2024-12-01)

Prevalence of Asthma and Asthma Severity Among Patients with Moderate–Severe Atopic Dermatitis Treated with Advanced Systemics
by: Maria O. Christensen, et al.
Published: (2025-06-01)

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
by: Hao Zhang, et al.
Published: (2025-07-01)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024-12-01)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
by: Sira Nanthapisal, et al.
Published: (2023-07-01)